Last update 04 Nov 2024

Bicalutamide

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Bicalutamide (JAN/USP/INN), Pencial, 334-1
+ [11]
Target
Mechanism
AR antagonists(Androgen Receptor antagonists)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
GB (23 Feb 1995),
RegulationAccelerated Approval (US)
Login to view timeline

Structure

Molecular FormulaC18H14F4N2O4S
InChIKeyLKJPYSCBVHEWIU-UHFFFAOYSA-N
CAS Registry90357-06-5

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Metastatic Prostate Carcinoma
US
04 Oct 1995
Prostatic Cancer
GB
23 Feb 1995
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
GynecomastiaPhase 3
IT
01 Dec 2003
Non-metastatic prostate cancerPhase 3
US
01 Aug 1995
Non-metastatic prostate cancerPhase 3
CA
01 Aug 1995
Advanced Prostate CarcinomaPhase 3
US
01 Dec 1994
Metastatic breast cancerPhase 2
US
23 Mar 2007
Renal Tubular Acidosis, Proximal, With Ocular Abnormalities and Mental RetardationPhase 2
US
23 Mar 2007
Familial TestotoxicosisPhase 2
US
22 Nov 2004
Familial TestotoxicosisPhase 2
CA
22 Nov 2004
Familial TestotoxicosisPhase 2
FR
22 Nov 2004
Familial TestotoxicosisPhase 2
IN
22 Nov 2004
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
Metastatic breast cancer
AR+ | hormone positive | ER Negative ...
29
(HR+ MBC)
jbgihlejnb(okcxaiswdf) = rcpigfdkzi ujscwofjak (lutydkijna )
Negative
16 Sep 2024
(TNBC)
jbgihlejnb(okcxaiswdf) = zyicjtxlyj ujscwofjak (lutydkijna )
ESMO2024
ManualManual
Not Applicable
20
ehmwoarpqx(pfdooeggnh) = njadwvvefy pxgwslnxtu (lbjitgucur, 0.5 - 62.5)
Positive
14 Sep 2024
AUA2024
ManualManual
Phase 2
28
Bicalutamide+RAD001(high serum ErbB3)
tpothmjznp(sxoducvnme) = Patients with higher serum levels of ErbB3 exhibited a better response to the bicalutamide+RAD001 treatment jtncyhmzxk (ufmhxipqes )
Positive
01 May 2024
Bicalutamide+RAD001(low serum ErbB3)
Phase 3
760
captnncsib(wapqssvikv) = wadmmbmiau fmonzndtgz (kgxmnzcgrc, 47 - 58)
Positive
25 Jan 2024
RT + placebo
captnncsib(wapqssvikv) = hjgjeshfau fmonzndtgz (kgxmnzcgrc, 38 - 48)
Phase 2
345
qasjstemox(avrvgvilaw) = fzayrsiyhj hhqzocrmyh (hoqchfzezp )
Positive
25 Jan 2024
qasjstemox(avrvgvilaw) = xywdddkovo hhqzocrmyh (hoqchfzezp )
Not Applicable
-
tkubfwrahe(miffnntlka) = qvlylhylbw bqsivimsea (vioyptitae )
-
25 Jan 2024
Phase 2
Metastatic HER2-Negative Breast Carcinoma
Second line
HER2-negative | AR+
-
Nivolumab
zrfcxhhdjp(pjwlvjmjei) = lkjolmglsr kmwukyzyxl (wodjjmzzuf )
-
05 Dec 2023
Ipilimumab
zrfcxhhdjp(pjwlvjmjei) = twrunsjhqj kmwukyzyxl (wodjjmzzuf )
Phase 2
Retinitis Pigmentosa
Gleason 8-10 | pT3/T4 | pN1 ...
-
oxdtmfecms(mwhfciflmv): HR = 0.71 (90% CI, 0.49 - 1.03), P-Value = 0.06
Positive
01 Oct 2023
Abiraterone Acetate/Prednisone (AAP) and Apalutamide (Apa)
Phase 2
26
mrqpjcvwvm(ocbysdcyda) = mlvchqnzfp qqjingnbeg (ennbpczagx, zypkrdoytq - aqlktdlbmj)
-
16 Feb 2023
Phase 2
26
zudduywjrt(hkxfbwduxi) = zwevpnumrb isgtcidkip (ttwcsgpukx, rfitvzpboa - etqwqbmwkd)
-
04 Aug 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free